Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cevec, the German developer of a new human expression system derived from amniocytes, has signed an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company. The agreement enables Pevion Biotech to exclusively use Cevec’s transient CAP-T cell expression technology to manufacture and commercialise a protein antigen for vaccination against human infectious disease.
Subscribe to our email newsletter
Following entry into toxicological studies and clinical Phases I to III, Cevec is expected to receive undisclosed milestone payments after market approval.
Cevec claimed that the transient CAP-T protein production technology is based on CAP cells, a human immortalised cell line for stable protein production derived from amniocytes and developed by the company.
The non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The platform allows efficient protein production from research, development and scale up to large scale manufacturing in high-volume bioreactors.
Pevion Biotech claimed that the target protein is part of a vaccine that the company intends to develop based on its proprietary and market-validated virosome technology platform.
Rainer Lichtenberger, CEO of Cevec, said: “The signing of this agreement is a milestone for Cevec since it represents our first exclusively granted license for a clinically relevant protein produced in our CAP cells.
“We’re proud that Pevion Biotech has chosen our CAP technology expression platform to produce a technically demanding protein.”